Palvella Therapeutics, Inc. (PVLA) stock
PVLANasdaqPharmaceutical PreparationsFiscal year ends December 31
$144.35−0.25 (-0.17%)
Close on Nov 17, 2026Market cap $2.08BP/E –Yield –
Palvella Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Palvella Therapeutics's profit margin for the twelve months ending Sep 30, 2024 was 1861.5%. For fiscal 2023 it was 43.7%, against -128.5% the year before. The highest annual figure on record is 43.7% in fiscal 2023.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | 43.7% | +172.1 |
| FY2022 | Dec 31, 2022 | -128.5% | +17.1 |
| FY2021 | Dec 31, 2021 | -145.6% | −18.6 |
| FY2020 | Dec 31, 2020 | -127.0% | −71.9 |
| FY2019 | Dec 31, 2019 | -55.0% | +36.9 |
| FY2018 | Dec 31, 2018 | -91.9% | −22.1 |
| FY2017 | Dec 31, 2017 | -69.8% | +321.2 |
| FY2016 | Dec 31, 2016 | -391.0% | +88.5 |
| FY2015 | Dec 31, 2015 | -479.5% | −295.9 |
| FY2014 | Dec 31, 2014 | -183.6% | −184.1 |
| FY2013 | Dec 31, 2013 | 0.5% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2024 | Mar 31, 2024 | -4784.9% | −4104.0 |
| Q4 FY2023 | Dec 31, 2023 | 2975.4% | +3114.0 |
| Q3 FY2023 | Sep 30, 2023 | -55.1% | +126.2 |
| Q2 FY2023 | Jun 30, 2023 | 19.8% | +299.4 |
| Q1 FY2023 | Mar 31, 2023 | -680.9% | −634.5 |
| Q4 FY2022 | Dec 31, 2022 | -138.6% | −25.7 |
| Q3 FY2022 | Sep 30, 2022 | -181.3% | +226.3 |
| Q2 FY2022 | Jun 30, 2022 | -279.6% | +192.2 |
| Q1 FY2022 | Mar 31, 2022 | -46.4% | −19.7 |
| Q4 FY2021 | Dec 31, 2021 | -112.9% | +654.3 |
| Q3 FY2021 | Sep 30, 2021 | -407.6% | +78.4 |
| Q2 FY2021 | Jun 30, 2021 | -471.8% | −427.8 |
| Q1 FY2021 | Mar 31, 2021 | -26.7% | +0.4 |
| Q4 FY2020 | Dec 31, 2020 | -767.2% | −762.7 |
| Q3 FY2020 | Sep 30, 2020 | -486.0% | −468.9 |
| Q2 FY2020 | Jun 30, 2020 | -44.0% | +176.5 |
| Q1 FY2020 | Mar 31, 2020 | -27.1% | +94.0 |
| Q4 FY2019 | Dec 31, 2019 | -4.5% | +233.3 |
| Q3 FY2019 | Sep 30, 2019 | -17.1% | +56.6 |
| Q2 FY2019 | Jun 30, 2019 | -220.5% | −218.8 |
| Q1 FY2019 | Mar 31, 2019 | -121.1% | +88.8 |
| Q4 FY2018 | Dec 31, 2018 | -237.7% | −279.0 |
| Q3 FY2018 | Sep 30, 2018 | -73.7% | +106.0 |
| Q2 FY2018 | Jun 30, 2018 | -1.7% | +542.5 |
| Q1 FY2018 | Mar 31, 2018 | -209.9% | +385.4 |
| Q4 FY2017 | Dec 31, 2017 | 41.3% | +281.8 |
| Q3 FY2017 | Sep 30, 2017 | -179.8% | +609.6 |
| Q2 FY2017 | Jun 30, 2017 | -544.3% | – |
| Q1 FY2017 | Mar 31, 2017 | -595.2% | – |
| Q4 FY2016 | Dec 31, 2016 | -240.5% | – |
| Q3 FY2016 | Sep 30, 2016 | -789.3% | – |
See a number that looks wrong?